GRETCHEN NALLEY: Open Payments
NPI 1376973909 · SILVERDALE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$901 in 43 payments from 14 companies in 2025. Trend: 2023 $1,545 · 2024 $825 · 2025 $901
Food & beverage: $901
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $236 |
| GlaxoSmithKline, LLC. | 9 | $174 |
| GENZYME CORPORATION | 5 | $104 |
| Novartis Pharmaceuticals Corporation | 4 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| CSL Behring | 2 | $45 |
| Genentech USA, Inc. | 2 | $42 |
| Ionis Pharmaceuticals, Inc. | 2 | $41 |
| BioCryst US Sales Co., LLC | 1 | $30 |
| Lilly USA, LLC | 1 | $20 |
Products named: NUCALA, TEZSPIRE, DUPIXENT, AIRSUPRA, Rhapsido, Hizentra, Xolair, DAWNZERA.
Industry payments across WA — which companies pay providers there.
